# Study of Denosumab in Subjects With Giant Cell Tumor of Bone

> **NCT00680992** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 535 (actual)

## Conditions studied

- Cancer
- Giant Cell Tumors
- Giant Cell Tumor of Bone
- Benign Giant Cell Tumors

## Interventions

- **DRUG:** Denosumab

## Key facts

- **NCT ID:** NCT00680992
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-09
- **Primary completion:** 2018-05-17
- **Final completion:** 2018-05-17
- **Target enrollment:** 535 (ACTUAL)
- **Last updated:** 2022-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00680992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00680992, "Study of Denosumab in Subjects With Giant Cell Tumor of Bone". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00680992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*